Novartis Analyst Targets Diverge as $2.2 Billion in Pipeline Setbacks Temper Post-Earnings Optimism
Published on 10/29/2026 at 14:51 | Editorial boerse-global.de
Novartis shares climbed 3.5% as a wave of analyst revisions followed Tuesday's quarterly report — but the direction of those revisions tells a more nuanced story than the headline gain suggests. Price targets moved higher at several houses, yet recommendations stayed largely cautious, leaving investors to weigh short-term earnings momentum against fresh pipeline setbacks and a pivotal capital markets day on 19 November 2026.
JPMorgan offered the most bullish voice, lifting its target to CHF 145 and reaffirming an "Overweight" rating. Analyst Richard Vosser raised revenue and per-share earnings estimates for the core business in 2026 and 2027, meaning the call rests on improved operating expectations rather than a simple re-rating of the stock. That gives the share price move a company-specific anchor beyond the figures Novartis published on Tuesday.
Bernstein Research moved the opposite way, trimming its target from CHF 132.84 to CHF 127.08 while keeping a market-neutral stance. Analyst Justin Smith cited downward revisions to medium-term forecasts, according to dpa-AFX. The split verdict is a reminder that the day's advance should not be read as a uniformly more optimistic analyst consensus.
Targets Rise, Ratings Hold
UBS raised its target from CHF 116 to CHF 130 but stayed at "Neutral." Analyst Matthew Weston lifted earnings estimates after re-examining the quarterly report and shifted the valuation base to 2027 — two separate changes that together explain the higher number. It is not a fresh buy call, a distinction that matters because a rising target does not automatically signal greater confidence in the remaining upside.
Should investors sell immediately? Or is it worth buying Novartis?
DZ Bank likewise kept "Halten" while nudging its target from CHF 130 to CHF 134. Other houses raised their objectives too, mostly without abandoning neutral ratings. The common thread: analysts value Novartis more highly, yet still see reasons for restraint.
Operating Leverage Behind the Beat
The third-quarter numbers give the optimists material to work with. Revenue came in at USD 14,522 million, up 4%, while core operating income advanced 11% — meaning profit grew nearly three times faster than sales. Novartis also upgraded its full-year guidance for core operating income: for 2026 it now expects anything from unchanged to low single-digit growth, compared with a previously guided low single-digit decline. Net sales guidance was left untouched at low single-digit growth.
Writedowns Cast a Shadow
Against that, Reuters reported roughly USD 2.2 billion in charges stemming from setbacks on two medicines. A USD 1.9 billion impairment relates to del-desiran, with USD 300 million tied to pelacarsen. The del-desiran hit follows a Phase III failure: the HARBOR trial in myotonic dystrophy type 1 missed its primary endpoint. The asset came to Novartis through its acquisition of Avidity Biosciences, so the disappointment touches both ongoing research and the valuation of a bought-in development program.
BioPharma Dive reported yesterday that del-desiran remains in development, with executives indicating a further Phase III study will likely be required — an expectation, not a confirmed announcement. Novartis is reviewing the full data set and holding talks with regulators.
Novartis at a turning point? This analysis reveals what investors need to know now.
A Win on the Other Side of the Ledger
Not all pipeline news pointed the same way. On 23 October, Novartis reported positive Phase III results for remibrutinib in relapsing multiple sclerosis. Annualized relapse rates fell by 35.2% and 31.2% versus teriflunomide across the two studies, and the company said no liver safety signal was observed. Novartis plans to file for approval on the strength of those data — a future revenue lever distinct from the sales and profits already booked.
The November Test
Weston expects the 19 November capital markets day to bring updated peak-sales targets for individual medicines and detail on medium-term prospects. Those disclosures could help investors balance the upgraded earnings estimates against the risks embedded in specific research programs. The higher targets show the recent study setbacks have not fully displaced confidence in earnings power; the unchanged ratings show where that confidence ends. A more convincing re-rating will depend on whether the long-term revenue story holds up after the writedowns.
Ad
Novartis Stock: New Analysis - 29 October
Fresh Novartis information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
